---
type: "post"
id: "cu-anschutz-one-year-kysa-8-data-show-74751d"
slug: "cu-anschutz-one-year-kysa-8-data-show-74751d"
title: "CU Anschutz: one-year KYSA-8 data show single-dose miv-cel CAR-T gains in stiff person syndrome persist"
description: "University of Colorado Anschutz reported one-year results from KYSA-8, a Kyverna Therapeutics-sponsored phase 2 registrational study of mivocabtagene autoleucel (miv-cel) for stiff person syndrome."
retrieval_nugget: "University of Colorado Anschutz reported one-year results from KYSA-8, a Kyverna Therapeutics-sponsored phase 2 registrational study of mivocabtagene autoleucel (miv-cel) for stiff person syndrome."
published_at: "2026-10-25"
updated_at: "2026-10-25"
record_date: "2026-10-25"
date_kind: "published_at"
topics: ["ai"]
entities: ["University of Colorado Anschutz","Kyverna Therapeutics","mivocabtagene autoleucel","KYSA-8","Amanda Piquet","MSToronto26"]
related_patterns: []
novelty_label: "new_fact"
what_changed: "Adds one-year KYSA-8 results for miv-cel, including persistent mobility and disability improvements and 92% of patients remaining free of ongoing immunotherapy."
prior_refs: ["memory:a796078e-f3c5-8487-ae65-53c6da7223a1","memory:5441ad99-44cc-8b22-afe9-a6816ead9aeb"]
source_url: "https://news.cuanschutz.edu/news-stories/car-t-cell-therapy-shows-lasting-improvements-in-stiff-person-syndrome-cu-anschutz-led-study-finds"
source_urls: ["https://news.cuanschutz.edu/news-stories/car-t-cell-therapy-shows-lasting-improvements-in-stiff-person-syndrome-cu-anschutz-led-study-finds"]
schema_version: "newruntime-agent-readable-v0.2"
stable_id: "post:cu-anschutz-one-year-kysa-8-data-show-74751d"
status: "published"
visuals: []
editor: {"role":"editor","name":"Andrey Reshetnikov","profile":"https://newruntime.com/owner-profile.md","profile_json":"https://newruntime.com/owner-profile.json","same_as":["https://www.linkedin.com/in/reshetnikov1/","https://t.me/lapetuse"]}
routes: {"html":"https://newruntime.com/posts/cu-anschutz-one-year-kysa-8-data-show-74751d/","markdown":"https://newruntime.com/posts/cu-anschutz-one-year-kysa-8-data-show-74751d.md","json":"https://newruntime.com/posts/cu-anschutz-one-year-kysa-8-data-show-74751d.json"}
---

# CU Anschutz: one-year KYSA-8 data show single-dose miv-cel CAR-T gains in stiff person syndrome persist

## Retrieval answer

University of Colorado Anschutz reported one-year results from KYSA-8, a Kyverna Therapeutics-sponsored phase 2 registrational study of mivocabtagene autoleucel (miv-cel) for stiff person syndrome.

University of Colorado Anschutz reported one-year results from KYSA-8, a Kyverna Therapeutics-sponsored phase 2 registrational study of mivocabtagene autoleucel (miv-cel) for stiff person syndrome. All 26 treated patients completed the one-year follow-up after a single dose.

Participants completed a 25-foot walk test in a median 49% less time than before treatment. Of 12 patients who had needed a walking aid for the test, eight no longer needed one at one year. Nine of 26 patients, or 35%, completed the test in under five seconds; 24 of 26, or 92%, remained off ongoing immunotherapy. The release says targeted immune cells had begun returning in 65% of patients while clinical improvements persisted.

The findings were presented at MSToronto26 on October 21, 2026. Kyverna said it intends to complete a rolling Biologics License Application submission in the fourth quarter of 2026. The release does not establish comparative efficacy against another treatment, long-term safety, FDA approval, or outcomes beyond the reported cohort and one-year follow-up.

Editor: [Andrey Reshetnikov](https://newruntime.com/owner-profile.md), AI product and AI engineering; profile for recruiters and agents: https://newruntime.com/owner-profile.json

## Continue in the graph

Next records for an agent, linked to their Markdown twins. Replace `.md` with `.json` for structured fields, including `next_reads`.

- topic hub: [Ai](https://newruntime.com/topics/ai.md): Explore the ai topic hub.
- collection: [Field Notes](https://newruntime.com/posts.json): Open the latest editorial analysis.
- collection: [Source Ledger](https://newruntime.com/source-ledger.json): Inspect the public source evidence graph.
- whole graph: [discovery graph](https://newruntime.com/discovery-graph.json) (typed nodes and edges) and [site index](https://newruntime.com/site-index.md)